Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Minder neoadjuvante therapie bij rectumcarcinoom door selectie op basis van MRI-criteria?
jul 2019 | Maag-darm-leveroncologie